Collegium Pharmaceutical, Inc. Aktie News

STOUGHTON, Mass., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced that its management will participate in the following investor conferences: Jefferies London Healthcare Conference Presentation Date and Time: Wednesday, November 19, 2025, at 8:00 a.m.

Collegium Pharmaceutical, Inc. just delivered standout Q3 results, with EPS and revenue significantly surpassing expectations, driving a 15% stock surge. COLL focuses on pain management treatments and expanded into ADHD with the recent Jornay PM acquisition, strengthening its product portfolio. Despite insider selling and a notable short interest, COLL maintains a strong cash position and manag...

Collegium Pharmaceutical, Inc. ( COLL ) Q3 2025 Earnings Call November 6, 2025 8:00 AM EST Company Participants Ian Karp Vikram Karnani - CEO, President, Executive VP & Director Scott Dreyer - Executive VP & Chief Commercial Officer Colleen Tupper - Executive VP & CFO Conference Call Participants Brandon Folkes - H.C. Wainwright & Co, LLC, Research Division Jeevan Larson - Truist Securities, In...

– Generated Record Quarterly Net Revenue of $209.4 Million, Up 31% Year-over-Year – – Generated Record Quarterly Jornay PM ® Net Revenue of $41.8 Million; Grew Prescriptions by 20% Year-over-Year – – Generated Record Quarterly Pain Portfolio Net Revenue of $167.6 Million, Up 11% Year-over-Year, with All Three Core Products Growing Year-over-Year – – Raised Full-Year 2025 Net Revenue Guidance to...

MONTREAL, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) ("Knight"), a pan-American (ex-USA) specialty pharmaceutical company, announced today the launch of JORNAY PM™ (methylphenidate HCI extended-release capsules) in Canada. JORNAY PM™ is an extended-release formulation of methylphenidate, a stimulant medication for the treatment of Attention-Deficit Hyperactivity Disor...

STOUGHTON, Mass., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced that it will report third quarter 2025 financial results before the market opens on Thursday, November 6, 2025.

STOUGHTON, Mass., Oct. 22, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced it will have poster presentations highlighting real-world data from its differentiated neuropsychiatry product, Jornay PM, (methylphenidate HCl), a central nervous system (CNS) stimulant for the treatment of attention deficit hyperactivity disorder (ADHD) in people 6 years of age an...

STOUGHTON, Mass., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced that its management team will ring the Nasdaq opening bell on October 14, 2025 at 9:30 a.m.